Drugs / Cinrebafusp alfa
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT03650348 | Aug 2018 → Aug 2022 | HER2 positive breast carcinoma, urinary bladder cancer | Pieris Pharmaceuticals GmbH | Completed | No outcome recorded |
| Phase 1 | NCT03330561 | Sep 2017 → Dec 2023 | HER2 positive breast carcinoma, urinary bladder cancer | Pieris Pharmaceuticals GmbH | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05190445 | Nov 2021 → Feb 2023 overdue | carcinoma | Pieris Pharmaceuticals GmbH | Active not recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Cinrebafusp alfa | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05190445 ↗ |
| Known as | PRS-343 | “cinrebafusp alfa (PRS-343) in combination with ramucirumab and paclitaxel” NCT05190445 ↗ |
| Action | Activate | “HER2 targeted CD137 agonist” NCT03330561 ↗ |
| Modality | Other / unclassified | “HER2/4-1BB Bispecific” NCT03650348 ↗ |
| Route | Intravenous | “administered by intravenous (IV) infusion” NCT03330561 ↗ |